Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Integrated genomic analyses identify ERRFI1 and TACC3 as glioblastoma-targeted genes.

Duncan CG, Killela PJ, Payne CA, Lampson B, Chen WC, Liu J, Solomon D, Waldman T, Towers AJ, Gregory SG, McDonald KL, McLendon RE, Bigner DD, Yan H.

Oncotarget. 2010 Aug;1(4):265-77.

2.

Integrative genome-wide analysis reveals a robust genomic glioblastoma signature associated with copy number driving changes in gene expression.

de Tayrac M, Etcheverry A, Aubry M, Saïkali S, Hamlat A, Quillien V, Le Treut A, Galibert MD, Mosser J.

Genes Chromosomes Cancer. 2009 Jan;48(1):55-68. doi: 10.1002/gcc.20618.

3.

The Wnt inhibitory factor 1 (WIF1) is targeted in glioblastoma and has a tumor suppressing function potentially by induction of senescence.

Lambiv WL, Vassallo I, Delorenzi M, Shay T, Diserens AC, Misra A, Feuerstein B, Murat A, Migliavacca E, Hamou MF, Sciuscio D, Burger R, Domany E, Stupp R, Hegi ME.

Neuro Oncol. 2011 Jul;13(7):736-47. doi: 10.1093/neuonc/nor036. Epub 2011 Jun 3.

4.

The evolving picture of the glioblastoma genome.

Parsons DW.

Oncotarget. 2010 Aug;1(4):237-8. No abstract available.

5.

The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma.

Parker BC, Annala MJ, Cogdell DE, Granberg KJ, Sun Y, Ji P, Li X, Gumin J, Zheng H, Hu L, Yli-Harja O, Haapasalo H, Visakorpi T, Liu X, Liu CG, Sawaya R, Fuller GN, Chen K, Lang FF, Nykter M, Zhang W.

J Clin Invest. 2013 Feb;123(2):855-65. doi: 10.1172/JCI67144. Epub 2013 Jan 9.

6.

Comprehensive genomic characterization defines human glioblastoma genes and core pathways.

Cancer Genome Atlas Research Network.

Nature. 2008 Oct 23;455(7216):1061-8. doi: 10.1038/nature07385. Epub 2008 Sep 4. Erratum in: Nature. 2013 Feb 28;494(7438):506.

7.

Monosomy of chromosome 10 associated with dysregulation of epidermal growth factor signaling in glioblastomas.

Yadav AK, Renfrow JJ, Scholtens DM, Xie H, Duran GE, Bredel C, Vogel H, Chandler JP, Chakravarti A, Robe PA, Das S, Scheck AC, Kessler JA, Soares MB, Sikic BI, Harsh GR, Bredel M.

JAMA. 2009 Jul 15;302(3):276-89. doi: 10.1001/jama.2009.1022.

9.

Identification of tumor suppressors and oncogenes from genomic and epigenetic features in ovarian cancer.

Wrzeszczynski KO, Varadan V, Byrnes J, Lum E, Kamalakaran S, Levine DA, Dimitrova N, Zhang MQ, Lucito R.

PLoS One. 2011;6(12):e28503. doi: 10.1371/journal.pone.0028503. Epub 2011 Dec 8.

10.

Focal chromosomal copy number aberrations identify CMTM8 and GPR177 as new candidate driver genes in osteosarcoma.

Both J, Krijgsman O, Bras J, Schaap GR, Baas F, Ylstra B, Hulsebos TJ.

PLoS One. 2014 Dec 31;9(12):e115835. doi: 10.1371/journal.pone.0115835. eCollection 2014.

11.

Integrated genomic profiling identifies candidate genes implicated in glioma-genesis and a novel LEO1-SLC12A1 fusion gene.

Bralten LB, Kloosterhof NK, Gravendeel LA, Sacchetti A, Duijm EJ, Kros JM, van den Bent MJ, Hoogenraad CC, Sillevis Smitt PA, French PJ.

Genes Chromosomes Cancer. 2010 Jun;49(6):509-17. doi: 10.1002/gcc.20760.

PMID:
20196086
12.

Integration of DNA copy number alterations and transcriptional expression analysis in human gastric cancer.

Fan B, Dachrut S, Coral H, Yuen ST, Chu KM, Law S, Zhang L, Ji J, Leung SY, Chen X.

PLoS One. 2012;7(4):e29824. doi: 10.1371/journal.pone.0029824. Epub 2012 Apr 23.

13.

Molecular characterization of long-term survivors of glioblastoma using genome- and transcriptome-wide profiling.

Reifenberger G, Weber RG, Riehmer V, Kaulich K, Willscher E, Wirth H, Gietzelt J, Hentschel B, Westphal M, Simon M, Schackert G, Schramm J, Matschke J, Sabel MC, Gramatzki D, Felsberg J, Hartmann C, Steinbach JP, Schlegel U, Wick W, Radlwimmer B, Pietsch T, Tonn JC, von Deimling A, Binder H, Weller M, Loeffler M; German Glioma Network.

Int J Cancer. 2014 Oct 15;135(8):1822-31. doi: 10.1002/ijc.28836. Epub 2014 Mar 28.

14.

Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities.

Maher EA, Brennan C, Wen PY, Durso L, Ligon KL, Richardson A, Khatry D, Feng B, Sinha R, Louis DN, Quackenbush J, Black PM, Chin L, DePinho RA.

Cancer Res. 2006 Dec 1;66(23):11502-13. Epub 2006 Nov 17.

15.

Frequent promoter hypermethylation and transcriptional downregulation of the NDRG2 gene at 14q11.2 in primary glioblastoma.

Tepel M, Roerig P, Wolter M, Gutmann DH, Perry A, Reifenberger G, Riemenschneider MJ.

Int J Cancer. 2008 Nov 1;123(9):2080-6. doi: 10.1002/ijc.23705.

16.

DNA copy number variation and gene expression analyses reveal the implication of specific oncogenes and genes in GBM.

Margareto J, Leis O, Larrarte E, Pomposo IC, Garibi JM, Lafuente JV.

Cancer Invest. 2009 Jun;27(5):541-8. doi: 10.1080/07357900802563044.

PMID:
19219654
17.

Integration of genomic analysis and in vivo transfection to identify sprouty 2 as a candidate tumor suppressor in liver cancer.

Lee SA, Ho C, Roy R, Kosinski C, Patil MA, Tward AD, Fridlyand J, Chen X.

Hepatology. 2008 Apr;47(4):1200-10. doi: 10.1002/hep.22169.

PMID:
18214995
18.

Somatic Copy Number Alterations at Oncogenic Loci Show Diverse Correlations with Gene Expression.

Roszik J, Wu CJ, Siroy AE, Lazar AJ, Davies MA, Woodman SE, Kwong LN.

Sci Rep. 2016 Jan 20;6:19649. doi: 10.1038/srep19649.

19.

KIAA1797/FOCAD encodes a novel focal adhesion protein with tumour suppressor function in gliomas.

Brockschmidt A, Trost D, Peterziel H, Zimmermann K, Ehrler M, Grassmann H, Pfenning PN, Waha A, Wohlleber D, Brockschmidt FF, Jugold M, Hoischen A, Kalla C, Waha A, Seifert G, Knolle PA, Latz E, Hans VH, Wick W, Pfeifer A, Angel P, Weber RG.

Brain. 2012 Apr;135(Pt 4):1027-41. doi: 10.1093/brain/aws045. Epub 2012 Mar 16.

PMID:
22427331
20.

Downregulation of RUNX3 and TES by hypermethylation in glioblastoma.

Mueller W, Nutt CL, Ehrich M, Riemenschneider MJ, von Deimling A, van den Boom D, Louis DN.

Oncogene. 2007 Jan 25;26(4):583-93. Epub 2006 Aug 14.

PMID:
16909125

Supplemental Content

Support Center